Kanserin Metabolik Yeniden Programlanması

Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47. doi:10.1016/j.cmet.2015.12.006

Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473. doi:10.1126/science.aaw5473

Yoshida GJ. Metabolic reprogramming: The emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34:111. doi:10.1186/s13046-015-0221-y

Han J, Li Q, Chen Y, Yang Y. Recent metabolomics analysis in tumor metabolism reprogramming. Front Mol Biosci. 2021;8:763902. doi:10.3389/fmolb.2021.763902

Nong S, Wei H, Zhang Y, Sun T, Peng X. Metabolic reprogramming in cancer: Mechanisms and therapeutic targets. Mol Oncol. 2023;17(3):587–608. doi:10.1002/mco2.218

Xiao Y, Wang S, Zhang Y, Liu J. Emerging therapies in cancer metabolism. Cell Rep Med. 2023;4(12):101234. doi:10.1016/j.xcrm.2023.101234

Warburg O. The metabolism of carcinoma cells. J Cancer Res. 1925;9:148–63.

Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–30.

Marchiq I, Pouyssegur J. Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H+ symporters. J Mol Med. 2016;94:155–71. doi:10.1007/s00109-015-1373-7

Payen VL, Mina E, Van Hee VF, Porporato PE, Sonveaux P. Monocarboxylate transporters in cancer. Mol Metab. 2020;33:48–66. doi:10.1016/j.molmet.2019.12.012

Polet F, Feron O. Endothelial cell metabolism and tumour angiogenesis: Glucose and glutamine as essential fuels and lactate as the driving force. J Intern Med. 2013;273:156–65. doi:10.1111/joim.12014

Mathew M, Nguyen NT, Bhutia YD, Sivaprakasam S, Ganapathy V. Metabolic signature of Warburg effect in cancer: An effective and obligatory interplay between nutrient transporters and catabolic/anabolic pathways to promote tumor growth. Cancers. 2024;16(3):504. doi:10.3390/cancers16030504

Reina-Campos M, Diaz-Meco MT, Moscat J. The complexity of the serine glycine one-carbon pathway in cancer. J Cell Biol. 2020;219:e201907022. doi:10.1083/jcb.201907022

Pan S, Fan M, Liu Z, Li X, Wang H. Serine, glycine and one-carbon metabolism in cancer. Int J Oncol. 2021;58:158–70. doi:10.3892/ijo.2020.5131

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013

Li X, Peng X, Li Y, Wei S, He G, Liu J, Li X, Yang S, Li D, Lin W, Fang J, Yang L, Li H. Glutamine addiction in tumor cell: Oncogene regulation and clinical treatment. Cell Commun Signal. 2024;22:12. doi:10.1186/s12964-023-01449-x

Eagle H, Oyama VI, Levy M, Horton CL, Fleischman R. The growth response of mammalian cells in tissue culture to L-glutamine and L-glutamic acid. J Biol Chem. 1956;218(2):607–16.

Kodama M, Oshikawa K, Shimizu H, Yoshioka S, Takahashi M, Izumi Y, et al. A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. Nat Commun. 2020;11(1):1320. doi:10.1038/s41467-020-15136-7

Ijare OB, Hambarde S, Brasil Da Costa FH, Lopez S, Sharpe MA, Helekar SA, et al. Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas. Neuro-Oncol. 2022;24(4):556–68. doi:10.1093/neuonc/noab265

Bergström J, Fürst P, Norée LO, Vinnars E. Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol. 1974;36(6):693–7. doi:10.1152/jappl.1974.36.6.693

Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion, and bioenergetics in ovarian cancer. Mol Syst Biol. 2014;10(5):728. doi:10.15252/msb.20145192

Tennant DA, Duran RV, Boulahbel H, Gottlieb E. Metabolic transformation in cancer. Carcinogenesis. 2009;30(8):1269–80. doi:10.1093/carcin/bgp146

Kandasamy P, Zlobec I, Nydegger DT, Pujol Giménez J, Bhardwaj R, Shirasawa S, et al. Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the Hippo signaling effector YAP1. Mol Oncol. 2021;15(10):2782–2800. doi:10.1002/1878-0261.13040

Hanada K, Kawada K, Nishikawa G, Toda K, Maekawa H, Nishikawa Y, et al. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer. Cancer Lett. 2021;522:129–41. doi:10.1016/j.canlet.2021.05.014

Wong CC, Xu J, Bian X, Wu J, Kang W, Qian Y, et al. In colorectal cancer cells with mutant KRAS, SLC25A22-mediated glutaminolysis reduces DNA demethylation to increase Wnt signaling, stemness, and drug resistance. Gastroenterology. 2020;159(6):2163–80.e7. doi:10.1053/j.gastro.2020.08.014

Najumudeen AK, Ceteci F, Fey SK, Hamm G, Steven RT, Hall H, et al. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nat Genet. 2021;53(1):16–26. doi:10.1038/s41588-020-00753-6

Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18(2):153–61. doi:10.1016/j.cmet.2013.05.017

Baenke F, Peck B, Miess H, Schulze A. Hooked on fat: The role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013;6(6):1353–63. doi:10.1242/dmm.011338

Khan I, Ullah N, Zubair H, Hedayat Khan M, Anwar S, Khan S. Lipid metabolism in cancer: A systematic review. Clin Nutr Open Sci. 2021;36:100–10. doi:10.1016/j.nutos.2021.09.003

Spinelli JB, Haigis MC. The multifaceted contributions of mitochondria to cellular metabolism. Nat Cell Biol. 2018;20:745–54. doi:10.1038/s41556-018-0124-1

Moindjie H, Rodrigues-Ferreira S, Nahmias C. Mitochondrial metabolism in carcinogenesis and cancer therapy. Cancers. 2021;13(13):3311. doi:10.3390/cancers13133311

Chaban Y, Boekema EJ, Dudkina NV. Structures of mitochondrial oxidative phosphorylation supercomplexes and mechanisms for their stabilisation. Biochim Biophys Acta Bioenerg. 2014;1837:418–26. doi:10.1016/j.bbabio.2013.10.002

Wu H, Ying M, Hu X. Lactic acidosis switches cancer cells from aerobic glycolysis back to dominant oxidative phosphorylation. Oncotarget. 2016;7:40621–40629. doi:10.18632/oncotarget.9770

Hui S, Ghergurovich JM, Morscher RJ, Jang C, Teng X, Lu W, et al. Glucose feeds the TCA cycle via circulating lactate. Nature. 2017;551:115–8. doi:10.1038/nature24057

Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV. MYC and metabolism on the path to cancer. Semin Cell Dev Biol. 2015;43:11–21. doi:10.1016/j.semcdb.2015.08.003

Ma Q, Zhang W, Wu K, Shi L. The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy. Mol Cancer. 2025;24:14. doi:10.1186/s12943-024-01400-x

Su WY, Tian LY, Guo LP, Huang LQ, Gao WY. PI3K signaling regulated metabolic reprogramming: From mechanism to application. Biochim Biophys Acta Rev Cancer. 2023;1878(5):188952. doi:10.1016/j.bbcan.2023.188952

Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and metabolism. J Mol Cell Biol. 2019;11(4):284–92. doi:10.1093/jmcb/mjz005

Hardie DG, Alessi DR. LKB1 and AMPK and the cancer–metabolism link: Ten years after. BMC Biol. 2013;11:36. doi:10.1186/1741-7007-11-36

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778–89. doi:10.1002/ijc.33588

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013

Khan M, Maryam A, Zhang C, Mehmood T, Ma T, Ma Y. Metabolic reprogramming in cancer cells: Emerging molecular mechanisms and novel therapeutic approaches. Biomed Res Int. 2022;2022:4215489. doi:10.1155/2022/4215489

Lukey MJ, Katt WP, Cerione RA. Targeting amino acid metabolism for cancer therapy. Drug Discov Today. 2017;22(5):796–804. doi:10.1016/j.drudis.2016.12.003

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28. doi:10.1186/s12943-021-01324-3hompson G, Galindo C. School–family relationships, school satisfaction and the academic achievement of young people. Educational Review. Routledge; 2017;69(2): 248–265.doi:10.1080/00131911.2016.1207613